Philippe Judlin1, Anne-Carole Jacquard2, Xavier Carcopino3, François Aubin4, André Dahlab2, Frédéric Mistretta5, Didier Not5, Pierre-Yves Boelle6, Olivier Aynaud7, Benoît Soubeyrand2. 1. Pôle de Gynécologie, Obstétrique et Reproduction, Maternité régionale universitaire de Nancy, 10, rue du Dr Heydenreich -CS 74213-54 042 Nancy Cedex, France. 2. Sanofi Pasteur MSD, 8, rue Jonas Salk, 69367 Lyon Cedex 07, France. 3. Department of Obstetrics and Gynaecology, Assistance Publique des Hôpitaux de Marseille (APHM), Hôpital Nord, Chemin des Bourrely, 13915 Marseille cedex 20, France. 4. EA3181, SFR FED 4234, Université de Franche-Comté, Bâtiment INSERM, 20 rue Françoise Dolto, 25000 Besançon, France. 5. RCTS, 38 Rue du Plat, 69002 Lyon, France. 6. Faculté de Médecine Pierre et Marie Curie, INSERM UMR S707, APHP, 27, rue de Chaligny, 75571 Paris, Cedex 12, France. 7. Dermatology Department, University Hospital Cochin, 89, rue d'Assas, 75006 Paris, France.
Abstract
UNLABELLED: Background The objective was to evaluate the effect of a HPV vaccination program on the incidence proportion of a proxy, genital warts (GW), in women in France. METHODS: The number of primary GW cases was prospectively recorded over two 4-month periods before (T0: Dec 2008 to March 2009) and after (T1: Dec 2011 to March 2012) a HPV vaccination program. A total of 160 gynaecologists participated in T0 and 189 in T1. Primary genital herpes (HSV) infection was used as a control. RESULTS: During T0, 39190 15- to 26 year-old women were seen, of whom 176 were diagnosed with GW (incidence proportion: 0.45%) and 155 with primary HSV infection (incidence proportion: 0.39%). During T1, 45628 females were seen [229 with GW (incidence proportion: 0.50%) and 202 with HSV (incidence proportion: 0.44%)]. In the 15-20 years age category, the incidence proportion of primary GW decreased from 0.41% to 0.30% (P=0.128) between T0 and T1, and the proportion of women newly diagnosed with primary genital herpes diseases slightly increased from 0.34% to 0.38% (P=0.620). In the 15-18 years age group, this decrease became significant (0.34% to 0.18%; P=0.048). CONCLUSIONS: A trend for a non-significant decreased incidence proportion of GW was observed in young women below 20 years who are more frequently vaccinated. This may be the result of HPV vaccination and suggests that a substantial increase in vaccine coverage could lead to a more pronounced decreased incidence proportion of GW in the future.
UNLABELLED: Background The objective was to evaluate the effect of a HPV vaccination program on the incidence proportion of a proxy, genital warts (GW), in women in France. METHODS: The number of primary GW cases was prospectively recorded over two 4-month periods before (T0: Dec 2008 to March 2009) and after (T1: Dec 2011 to March 2012) a HPV vaccination program. A total of 160 gynaecologists participated in T0 and 189 in T1. Primary genital herpes (HSV) infection was used as a control. RESULTS: During T0, 39190 15- to 26 year-old women were seen, of whom 176 were diagnosed with GW (incidence proportion: 0.45%) and 155 with primary HSV infection (incidence proportion: 0.39%). During T1, 45628 females were seen [229 with GW (incidence proportion: 0.50%) and 202 with HSV (incidence proportion: 0.44%)]. In the 15-20 years age category, the incidence proportion of primary GW decreased from 0.41% to 0.30% (P=0.128) between T0 and T1, and the proportion of women newly diagnosed with primary genital herpes diseases slightly increased from 0.34% to 0.38% (P=0.620). In the 15-18 years age group, this decrease became significant (0.34% to 0.18%; P=0.048). CONCLUSIONS: A trend for a non-significant decreased incidence proportion of GW was observed in young women below 20 years who are more frequently vaccinated. This may be the result of HPV vaccination and suggests that a substantial increase in vaccine coverage could lead to a more pronounced decreased incidence proportion of GW in the future.